latest news releases from the newsroom
REVA Medical, Inc.
Details for REVA's Special Meeting of Stockholders
SAN DIEGO, Oct. 22, 2014 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) ("REVA" or the "Company") will hold a Special Meeting of Stockholders (the "Special Meeting") on Friday 31 October 2014 at 10:30 a.m. AEDT (which is 4:30 p.m. US PDT on Thursday, October 30, 2014). The meeting will be held at the AGL Theatre in the Museum of Sydney located at the corner of Phillip and Bridge Streets in Sydney, Australia.
Farmers Capital Bank Corporation
Farmers Capital Bank Corporation Announces Third Quarter Earnings
FRANKFORT, Ky., Oct. 22, 2014 (GLOBE NEWSWIRE) -- Farmers Capital Bank Corporation (Nasdaq:FFKT) (the "Company") reported net income of $4.1 million or $.49 per common share for the third quarter and $12.3 million or $1.44 per common share for the first nine months of 2014. Net income for the current quarter decreased $717 thousand or 14.9% compared with the current year second quarter, which represents a decrease of $.08 per common share. Compared to their respective year ago periods, net income increased $1.1 million or 35.3% for the third quarter and $1.9 million or 18.6% for the first nine months. On a per common share basis, net income increased $.15 or 44.1% and $.25 or 21.0% when compared with the prior-year three and nine month periods, respectively.
MediciNova Announces FDA Granted Orphan Drug Designation to MN-001 (tipelukast) for Idiopathic Pulmonary Fibrosis (IPF)
LA JOLLA, Calif., Oct. 22, 2014 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation to MN-001 (tipelukast) for treatment of idiopathic pulmonary fibrosis (IPF). Orphan-drug designation will provide MediciNova with seven years of marketing exclusivity for MN-001 (tipelukast) for the treatment of IPF if it is approved for this indication.
Alliance for Bangladesh Worker Safety
Alliance for Bangladesh Worker Safety Engages University of Texas to Conduct Independent Impact Assessment of Safety Trainings
WASHINGTON, D.C., Oct. 22, 2014 (GLOBE NEWSWIRE) -- via PRWEB - The Alliance for Bangladesh Worker Safety announced today that it has contracted with the University of Texas Health Science Center at Houston to conduct an independent assessment of the Alliance basic fire safety training for garment factory workers in Bangladesh. The project team will be led by Dr. Hasanat Alamgir, a University of Texas (UT) School of Public Health associate professor of occupational health at the Program in Environmental and Occupational Health Sciences. The team will conduct a research study to yield valid and reliable results, collect data through randomized surveys and focus groups from workers, and ultimately deliver a detailed report on the effectiveness of the Alliance worker training. This report will help identify areas of improvement as the Alliance training programs continue and expand the in the coming years.